Medikamenten-Guide

109 Artikel

Alle Artikel
Medikamenten-Guide

GLP-1 Dose Tracker: Log Your mg & Titration Schedule

A GLP-1 dose tracker logs which milligram you took on which date and follows your titration — Wegovy 0.25→2.4, Zepbound 2.5→15. See how to track and share it.

5 Min. Lesezeit
Medikamenten-Guide

Injection Tracker App for GLP-1: Features to Look For

Choosing an injection tracker app for GLP-1? Here are the must-have features — site-rotation body map, weekly reminders, dose log, missed-dose logic — and why it beats paper.

5 Min. Lesezeit
Medikamenten-Guide

Oral Wegovy Side Effects: Nausea & Warnings (2026)

Oral Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild-to-moderate and worst during dose increases. Because oral Wegovy is the same molecule as injectable Wegovy (semaglutide), it shares the *same* side-effect profile and the *same* serious warnings, including pancreatitis, gallbladder disease, and a boxed thyroid warning.

10 Min. Lesezeit
Medikamenten-Guide

Orforglipron Side Effects: Nausea, Warnings (2026)

Orforglipron's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — which are dose-dependent, tend to be worst around each dose increase, and usually settle as the body adapts. Rare but serious risks include a boxed warning for thyroid C-cell tumors plus pancreatitis and gallbladder disease, which need urgent medical care.

8 Min. Lesezeit
Medikamenten-Guide

Retatrutide Side Effects: Trial Data & Warnings 2026

In clinical trials, retatrutide's most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild-to-moderate and worst during dose escalation. Its triple-agonist design also produces two distinctive signals: abnormal skin sensations (dysesthesia) and a modest heart-rate increase. Retatrutide is investigational and available only through clinical trials — it cannot be prescribed.

7 Min. Lesezeit
Medikamenten-Guide

Semaglutide vs Tirzepatide: Which Is Right for You? (2026)

Tirzepatide (Mounjaro, Zepbound) acts on two hormones (GIP + GLP-1) and produced greater average weight loss in trials (~21%) than semaglutide (Ozempic, Wegovy, ~15%). But semaglutide has the longer track record and strong cardiovascular data. The "better" one depends on your goals, tolerance, cost, and prescriber.

4 Min. Lesezeit
Medikamenten-Guide

GLP-1 Side Effects: Ozempic, Wegovy & Tirzepatide Guide (2026)

The most common GLP-1 side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — and they are usually mild, most likely when starting or increasing the dose, and tend to ease within a few weeks. Rare but serious risks include pancreatitis, gallbladder problems, and severe delayed stomach emptying, which need urgent medical attention.

8 Min. Lesezeit
Medikamenten-Guide

How Much Does Wegovy & Ozempic Cost in 2026? Full Price Breakdown

Without insurance, Ozempic and Wegovy have list prices of roughly $970–$1,350 per month. But almost nobody pays that. Through the manufacturer's cash-pay pharmacy (NovoCare), self-pay prices in 2026 are about $349–$499/month for the injection and $149–$299/month for the newer oral pill — and with commercial insurance plus a savings card, eligible patients can pay as little as $0–$25 a month.

7 Min. Lesezeit
Medikamenten-Guide

Mounjaro Side Effects: Nausea, Sulfur Burps & Timeline (2026)

Mounjaro's most common side effects are gastrointestinal — nausea, diarrhea, decreased appetite, vomiting, and constipation — usually mild and worst during dose increases. Many users also report sulfur ("egg") burps. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

9 Min. Lesezeit
Medikamenten-Guide

Ozempic Side Effects: Nausea, Timeline & Warnings (2026)

Ozempic's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

9 Min. Lesezeit
Medikamenten-Guide

Semaglutide Side Effects: Ozempic, Wegovy & Rybelsus (2026)

Semaglutide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Frequency depends on the product and dose: highest with Wegovy 2.4 mg (weight loss), lower with Ozempic and oral Rybelsus (diabetes). Rare serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 Min. Lesezeit
Medikamenten-Guide

Tirzepatide Side Effects: Mounjaro & Zepbound (2026)

The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent medical care.

9 Min. Lesezeit
Medikamenten-Guide

Wegovy Side Effects: Nausea, Hair Loss & Timeline (2026)

Wegovy's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Because Wegovy titrates to a higher 2.4 mg dose, these are reported more often than with Ozempic. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying.

10 Min. Lesezeit
Medikamenten-Guide

Zepbound Side Effects: Nausea, Hair Loss & Timeline (2026)

Zepbound's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, and abdominal pain — usually mild and worst during dose increases. Injection-site reactions and hair loss are also labeled. Rare but serious risks include pancreatitis, gallbladder disease, and severe delayed stomach emptying, which need urgent care.

11 Min. Lesezeit
Medikamenten-Guide

GLP-1 allein reicht nicht – Das von WHO/ADA empfohlene Modell 'Medikament + Verhaltenstherapie' und HAVITs M0/M1/M2-Phasen

GLP-1-Rezeptoragonisten (Wegovy, Mounjaro, Zepbound) erzielen durchschnittlich 15–22% Gewichtsverlust (STEP 1, SURMOUNT-1). Doch STEP 4 berichtete +11,6 Prozentpunkte Wiederzunahme ein Jahr nach Absetzen – etwa 78% des Gewichtsverlusts kehrten zurück. WHO (2022) und ADA Standards (2024) empfehlen ausdrücklich Verhaltenstherapie zusätzlich zur Pharmakotherapie, und STEP 3 (JAMA 2021) zeigte, dass intensive Verhaltenstherapie in Kombination nahezu den 3-fachen Gewichtsverlust der Standard-Kombination erreichte (−16% vs. −5,7%). HAVIT strukturiert dies in 3 Phasen – vor Medikation (M0), Anpassung (M1), Erhaltung/Absetzen (M2) – und integriert Medikamente, Muskelerhalt und Verhaltenslernen. HAVIT verschreibt keine GLP-1-Medikamente; Verschreibung, Dosierung und Absetzen bleiben Aufgabe des Arztes.

14 Min. Lesezeit

Bereit für smarteres Abnehmen?

Alles, was du brauchst, um abzunehmen, Muskeln zu erhalten und gesunde Gewohnheiten aufzubauen — in einer KI-App.

Download on the App StoreGet it on Google Play

Kostenloser Download. In-App-Käufe möglich.